Bortezomib is a proteasome inhibitor approved for the treatment of multiple myeloma (MM). It is reported to cause cutaneous reactions such as erythema multiforme, vasculitis, Sweet syndrome, and histiocytoid Sweet syndrome. Herein, we report a case of bortezomib-induced Sweet-like syndrome. A 65-year-old man was referred to dermatology department for asymptomatic erythematous to purpuric plaques on the face, chest, and hands which developed 2 weeks ago. He was receiving sixth cycle of chemotherapy with bortezomib for treatment of MM. He was afebrile and laboratory studies showed no neutrophilia. Skin biopsies from chest and dorsum of left hand exhibited perivascular mononuclear cell infiltration without atypia and a few eosinophils. Immunohistochemical stainings for CD68 and MPO were positive. Taking account of temporal relationship between drug use and clinical presentation, absence of fever and neutrophilia, and the histopathologic findings, we diagnosed a bortezomib-induced Sweet-like syndrome.